Cardiopatías Familiares e xenética cardiovascular
University of Glasgow
Glasgow, Reino UnidoPublicacións en colaboración con investigadores/as de University of Glasgow (4)
2024
-
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM
Journal of the American Heart Association, Vol. 13, Núm. 15, pp. e035993
-
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4
Journal of Cardiac Failure
-
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM
Journal of the American College of Cardiology, Vol. 84, Núm. 19, pp. 1821-1831
2023
-
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
Journal of the American College of Cardiology, Vol. 81, Núm. 1, pp. 34-45